A 38-year-old Hispanic man was admitted to the telemetry floor with diagnosis of pericarditis. Blood cultures revealed methicillin-sensitive Staphylococcus aureus and the patient was started on nafcillin. Despite appropriate antibiotic therapy, the patient remained febrile. Transesophageal echocardiogram (TEE) was performed to evaluate for endocarditis. An hour after the TEE, patient started to desaturate and complained of shortness of breath. At this point, the patient was afebrile, with a pulse rate of 110 beats/minute and blood pressure of 97/63 mm Hg. Oxygen saturation by pulse oximetry of 82% on room air progressively declined even with administration of supplemental oxygen to 77%, necessitating intubation. Despite mechanical ventilation with 100% oxygen delivery, the patient remained cyanotic, with pulse oximetry reading of 69%, and with the arterial blood obtained from the patient at this time for laboratory analysis appearing brown in color.
Discussion
Methemoglobin is the state in which ferrous (Fe 2þ ) ions of heme are oxidized to the ferric state (Fe 3þ ). Because red blood cells are continuously exposed to various oxidative stresses, a methemoglobinemia level of approximately 1% is present in normal individuals at baseline. This low level is maintained through reduction by enzyme systems within the erythrocyte. The most important is the reduced nicotinamide adenine dinucleotide (NADH)-cytochrome-b5 reductase system. 1 Others, functioning mainly as reserve systems, are ascorbic acid, reduced glutathione, and reduced nicotinamide adenine dinucleotide phosphate (NADPH)-methemo-globin reductase. The latter requires a natural cofactor or an autooxidizable dye such as methylene blue for activity.
Methemoglobinemia can be congenital or acquired. Congenital methemoglobinemia is very rare and is due to a cytochrome-b5 reductase deficiency or presence of an abnormal hemoglobin M molecule. 2 Acquired methemoglobinemia, the more common type, results from exposure to chemicals that cause more rapid accumulation of methemoglobin than the rate at which methemoglobin can be reduced. Many chemical and environmental agents can cause acquired methemoglobinemia (Table 1) . Local anesthetics are the most common hospital-based pharmacologic agents to cause methemoglobinemia. Prilocaine has been implicated most frequently, especially in newborns. Prilocaine-induced methemoglobinemia is dose-dependent and occurs when doses used exceed 600 mg in a 24-hour period. Lidocaine is a rare cause of methemoglobinemia, but comorbidities like renal failure and use of other local anesthetics like benzocaine will increase the chances of methemoglobinemia. Benzocaine has been reported to cause methemoglobinemia after its use as a lubricant on endotracheal, bronchoscopic, and nasogastric or orogastric tubes, but more commonly after its use as a spray. Benzocaine is lipophilic and may continue to enter the bloodstream from adipose tissue after methylene blue concentrations are no longer therapeutic.
Clinical presentation varies based on methemoglobin levels. Early symptoms of methemoglobinemia, when the blood contains 15% to 50% methemoglobin, include nonspecific headache, fatigues, dyspnea, and lethargy. As the amount of methemoglobin in the blood exceeds 50%, the patients develop more serious neurological symptoms, ranging from confusion to seizures, respiratory depression, and death ( Table 2) . Clinical interpretation of methemoglobin levels must take into account the total hemoglobin value because anemic patients will have proportionately less functional hemoglobin. 3 Methemoglobinemia that develops rapidly will be clinically more severe than a similar degree that develops gradually. The acute accumulation of <30% methemoglobinemia is usually well tolerated in the nonanemic patient.
The suspicion for methemoglobinemia should be raised in the presence of dark or ''chocolate-brown'' arterial blood that does not become red with exposure to air. 4 Dark-colored blood from patients with hypoxia should redden with exposure to air; blood darkened by methemoglobin does not. The suspicion for methemoglobinemia should also be raised in the presence of a ''saturation gap,'' when the measured oxygen saturation of blood by pulse oximetry is less than the oxygen saturation calculated by routine blood gas analysis by more than 5%. 5 The oxygen saturation on arterial blood gas is calculated from partial pressure of arterial oxygen (PaO 2 ) and pH. Since PaO 2 is within normal limits in methemoglobinemia, it leads to a normal, though inaccurate, calculated oxygen saturation. Multiple-wavelength cooximetry is the accepted standard for confirming and quantifying methemoglobinemia. 6 This assay involves measuring methemoglobin at its peak absorbance of 630 nm and requires the addition of cyanide to convert methemoglobin to cyanomethemoglobin, which absorbs at shorter wavelengths, resulting in an absorbance decrease at 630 nm due to the disappearance of methemoglobin. Hyperlipidemia and intravenous administration of methylene blue or other dyes may interfere with cooximetry measurements.
In asymptomatic patients with acute methemoglobinemia, discontinuation of the offending drug and proper monitoring is sufficient. In patients who are symptomatic, in addition to supplemental oxygen, methylene blue should be used to enhance the reducing capacity of erythrocytes. Methylene blue, given intravenously in a dose of 1 mg/kg over 5 minutes, acts as an electron acceptor, enhances the NADPH pathway, and rapidly reduces methemoglobin to hemoglobin. 7 However, methylene blue should not be used in patients with glucose-6-phosphate dehydrogenase deficiency as it can cause life-threatening hemolysis. In these patients, ascorbic acid should be used. Hyperbaric oxygen or exchange transfusion can also be used. In patients who are in shock secondary to the methemoglobinemia, blood transfusion or exchange transfusion is helpful.
Summary
Agents that inflict large oxidative stress, such as topical anesthetics, can cause methemoglobinemia. A frequentlyused topical anesthetic agent like benzocaine is a common cause of methemoglobinemia. The most characteristic findings of methemoglobinemia are blue-gray or brown-gray cyanosis of the skin, lips, and nail beds, dark brown color of Serious neurological symptoms ranging from confusion to seizures; respiratory depression and death the blood, and ''saturation gap.'' Symptomatic patients should be given methylene blue intravenously.
